JP2022540000A5 - - Google Patents
Info
- Publication number
- JP2022540000A5 JP2022540000A5 JP2021576778A JP2021576778A JP2022540000A5 JP 2022540000 A5 JP2022540000 A5 JP 2022540000A5 JP 2021576778 A JP2021576778 A JP 2021576778A JP 2021576778 A JP2021576778 A JP 2021576778A JP 2022540000 A5 JP2022540000 A5 JP 2022540000A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- fluoro
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868057P | 2019-06-28 | 2019-06-28 | |
| US62/868,057 | 2019-06-28 | ||
| US202062960817P | 2020-01-14 | 2020-01-14 | |
| US62/960,817 | 2020-01-14 | ||
| US202063031719P | 2020-05-29 | 2020-05-29 | |
| US63/031,719 | 2020-05-29 | ||
| PCT/IB2020/056066 WO2020261205A1 (en) | 2019-06-28 | 2020-06-26 | Thieno[3,2-b]thiophene-2-carboxylic acid compounds having bckdk inhibiting activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022540000A JP2022540000A (ja) | 2022-09-14 |
| JP2022540000A5 true JP2022540000A5 (https=) | 2023-06-02 |
Family
ID=71452516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576778A Pending JP2022540000A (ja) | 2019-06-28 | 2020-06-26 | Ｂｃｋｄｋ阻害活性を有するチエノ［３，２－ｂ］チオフェン－２－カルボン酸化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11542270B2 (https=) |
| EP (1) | EP3990461A1 (https=) |
| JP (1) | JP2022540000A (https=) |
| CA (1) | CA3144869C (https=) |
| PY (1) | PY2030111A (https=) |
| TW (1) | TW202115086A (https=) |
| UY (1) | UY38768A (https=) |
| WO (1) | WO2020261205A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202115086A (zh) * | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
| TW202140058A (zh) | 2020-01-30 | 2021-11-01 | 美商美國禮來大藥廠 | 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途 |
| JP7826324B2 (ja) * | 2021-01-27 | 2026-03-09 | コーニンクレッカ フィリップス エヌ ヴェ | 肝線維症をモニタリングする磁気共鳴及び超音波せん断波エラストグラフィの解釈の向上のための装置及び方法 |
| WO2022175959A1 (en) * | 2021-02-21 | 2022-08-25 | Ramino-Bio | Thiophene based compounds and use thereof as bckdk inhibitors |
| US12605702B2 (en) | 2021-04-26 | 2026-04-21 | Reprieve Cardiovascular, Inc. | Measuring and/or detecting analytes in urine, and associated systems, devices, and methods |
| US20230010793A1 (en) * | 2021-07-12 | 2023-01-12 | Reprieve Cardiovascular, Inc. | Fluid therapy based on estimated excess fluid, and associated systems and methods |
| CA3240990A1 (en) | 2021-12-01 | 2023-06-08 | Pfizer Inc. | 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure |
| CN114903994A (zh) * | 2022-04-19 | 2022-08-16 | 上海交通大学医学院附属瑞金医院 | Bckdk作为靶点在制备2型糖尿病药物中的应用 |
| EP4695226A1 (en) | 2023-04-14 | 2026-02-18 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| US12257416B1 (en) | 2023-09-12 | 2025-03-25 | Reprieve Cardiovascular, Inc. | Fluid therapy based on sodium excretion, and associated systems, devices, and methods |
| WO2025153045A1 (zh) * | 2024-01-18 | 2025-07-24 | 上海拓界生物医药科技有限公司 | 一种吡啶并噻吩-2-羧酸衍生物及其制备方法和用途 |
| TW202539633A (zh) | 2024-02-01 | 2025-10-16 | 美商輝瑞股份有限公司 | 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途 |
| WO2025175244A1 (en) | 2024-02-16 | 2025-08-21 | Reprieve Cardiovascular, Inc. | Urine output sensing without use of an indwelling catheter, and associated systems, devices, and methods |
| US20250326741A1 (en) | 2024-04-22 | 2025-10-23 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026013531A1 (en) | 2024-07-10 | 2026-01-15 | Pfizer Inc. | Spiro[2.5]octane compounds |
| WO2026033382A1 (en) | 2024-08-07 | 2026-02-12 | Pfizer Inc. | Heterocyclic glp-1r modulators |
| WO2026042018A1 (en) | 2024-08-21 | 2026-02-26 | Pfizer Inc. | 4-{4-[(1-{[4-(propan-2-yl)phenyl]carbamoyl)-d-prolyl)amino]cyclohexyl}benzoic acid derivatives as gipr antagonists for the treatment of diabetes |
| WO2026078617A1 (en) | 2024-10-11 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078672A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078674A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078670A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists |
| WO2026078671A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic compounds as glucose-dependent insulinotropic polypeptide receptor antagonists |
| WO2026078673A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1992018106A1 (fr) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Procede de production d'une dispersion solide |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| ES2287971T3 (es) | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
| HUP0104634A3 (en) | 1998-07-06 | 2002-11-28 | Bristol Myers Squibb Co | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| OA12274A (en) * | 2000-05-22 | 2006-05-09 | Aventis Pharma Inc | Arylmethylamine derivatives for use as tryptase inhibitors. |
| GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
| GB0021831D0 (en) * | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| PL1753748T3 (pl) | 2004-05-12 | 2010-01-29 | Pfizer Prod Inc | Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV |
| EP2010520B1 (en) | 2006-04-20 | 2012-09-12 | Pfizer Products Inc. | Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases |
| EP2057162A2 (en) * | 2006-06-30 | 2009-05-13 | Sepracor Inc. | Fused heterocyclic inhibitors of d-amino acid oxidase |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| JP2011529483A (ja) | 2008-07-29 | 2011-12-08 | ファイザー・インク | フッ素化ヘテロアリール |
| AU2009286380B2 (en) | 2008-08-28 | 2011-09-15 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
| CA2754685A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Substituted indazole amides |
| EP2604604A1 (en) | 2009-03-11 | 2013-06-19 | Pfizer Inc | Benzofuranyl derivatives used as glucokinase inhibitors |
| WO2010106457A2 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| US20120052130A1 (en) | 2009-05-08 | 2012-03-01 | Pfizer Inc. | Gpr 119 modulators |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| NZ596467A (en) | 2009-06-05 | 2014-01-31 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| WO2011011781A1 (en) | 2009-07-24 | 2011-01-27 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
| US20120022116A1 (en) | 2010-07-20 | 2012-01-26 | Huayun Deng | Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex |
| KR102314286B1 (ko) | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| PT3621960T (pt) | 2017-05-11 | 2021-09-16 | Bristol Myers Squibb Co | Tienopiridinas e benzotiofenos úteis como inibidores de irak4 |
| TW202115086A (zh) * | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
-
2020
- 2020-06-24 TW TW109121446A patent/TW202115086A/zh unknown
- 2020-06-26 UY UY0001038768A patent/UY38768A/es not_active Application Discontinuation
- 2020-06-26 PY PY202002030111A patent/PY2030111A/es unknown
- 2020-06-26 US US16/912,828 patent/US11542270B2/en active Active
- 2020-06-26 JP JP2021576778A patent/JP2022540000A/ja active Pending
- 2020-06-26 EP EP20736441.5A patent/EP3990461A1/en active Pending
- 2020-06-26 WO PCT/IB2020/056066 patent/WO2020261205A1/en not_active Ceased
- 2020-06-26 CA CA3144869A patent/CA3144869C/en active Active
- 2020-10-23 US US17/078,257 patent/US11059833B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022540000A5 (https=) | ||
| US8569339B2 (en) | Soluble guanylate cyclase activators | |
| CN101903356B (zh) | 4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用 | |
| US10017468B2 (en) | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | |
| JP7217273B2 (ja) | ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用 | |
| US9273029B2 (en) | Pyridine-and pyrazine derivatives | |
| US9150575B2 (en) | Piperidinylpyrazolopyridine derivative | |
| JP5301456B2 (ja) | ヘテロアリールオキシキナゾリン誘導体 | |
| HRP20230631T1 (hr) | Agonisti receptora glp-1 i njihova upotreba | |
| US20240294525A1 (en) | Compounds as glp-1 receptor agonists and uses thereof | |
| US20100190980A1 (en) | Pyrazinamide compound | |
| CN114728168A (zh) | 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途 | |
| HRP20221437T1 (hr) | Agonisti receptora glp-1 i njihova upotreba | |
| JP2020521730A5 (https=) | ||
| JP2022538576A5 (https=) | ||
| RU2019111882A (ru) | Антагонисты trpv4 | |
| JP2011502982A5 (https=) | ||
| AU2015313829A1 (en) | Fused heterocyclic compounds as GPR120 agonists | |
| US20120214735A1 (en) | Acetamide derivatives as glucokinase activators, their process and medicinal applications | |
| TW201534606A (zh) | 醛固酮合成酶抑制劑 | |
| JPWO2009081782A1 (ja) | Ｎ−ピラゾール−２−ピリジンカルボキサミド誘導体 | |
| WO2012129967A1 (zh) | 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 | |
| TW201039827A (en) | Indoline compound | |
| RU2024114883A (ru) | Производные 3-фенил-1-бензотиофен-2-карбоновой кислоты в качестве ингибиторов киназы дегидрогеназы альфа-кетокислот с разветвленной цепью для лечения диабета, заболеваний почек, nash и сердечной недостаточности | |
| IL319486A (en) | HSD17B13 Inhibitors and/or Retarders |